期刊文献+

卡那单抗的药理与临床研究

Pharmacological and clinical studies of canakinumab
原文传递
导出
摘要 卡那单抗(canakinumab)2009年6月经FDA批准上市,用于治疗儿童和成人冷吡啉相关周期性综合征(cryopyrin-associated periodic syndrome,CAPS),包括并限于家族性寒冷型自身炎症性综合征(famil-ial cold auto-inflammatory syndrome,FCAS)与穆-韦综合征(Muckle-Wells syndrome,MWS)。文中对该药的作用机制、药理作用、临床研究等进展作一综述。 Canakinumab,which was approved by FDA in June 2009,is used for the treatment of cryopyrin associated periodic syndrome(CAPS): familial cold auto-inflammatory syndrome(FCAS) and Muckle-Wells syndrome(MWS).In this paper we reviewed the pharmacology and clinical studies of canakinumab.
出处 《中国新药杂志》 CAS CSCD 北大核心 2010年第16期1389-1391,共3页 Chinese Journal of New Drugs
关键词 卡那单抗 冷吡啉相关周期性综合征 药理作用 临床研究 canakinumab cryopyrin-associated periodic syndromes(CAPS) pharmacology clinical study
  • 相关文献

参考文献10

  • 1HAWKINS PN, LACHMANN HJ, AGANNA E,et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra[J]. Arthritis Rheum, 2004, 50(2): 607-612.
  • 2SHINKAI K, MCCALMONT TH, LESLIE KS. Cryopyrin-associated periodic syndromes and autoinflammation [J]. Clin Exp Dermatol, 2008, 33(1) : 1 -9.
  • 3ROSENGREN S, MUELLER JL, ANDERSON JP, et al. Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia [ J ]. J Allergy Clin Immunol, 2007, 119(4) : 991 -996.
  • 4STACK JH, BEAUMONT K, LARSEN PD, et al. IL-converting enzyme/caspase-I inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients[ J]. J Immunol, 2005, 175(4) : 2630 -2634.
  • 5FDA. Label and approval history[EB/OL]. (2009 -07 -20). http ://wwwaccessdatafdagov/scripts/cder/drugsatfda/indexcfm? fuseaction = SearchLabel_ApprovalHistory.
  • 6FERRER E, MORAL MA, BOZZO J. Muckle-Wells syndrome [J]. Drugs Fut, 2007,32(10): 919-924.
  • 7ALTEN R, GRAM H, JOOSTEN LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis[J]. Arthritis Res Ther, 2008,10 ( 3 ) : R67.
  • 8RUPERTO N, QUARTIER P, WULFFRAAT N, et al. A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZgg5), to evaluate preliminary dosing, safety and efficacy profile in children with systemic juvenile idiopathic arthritis [J]. Pediatr Rheumatol,2008, 6 ( Suppl 1 ) : S2.
  • 9KUMMERLE-DESCHNER JB, TZARIBACHEV N, HANSMANN S,et al. Long lasting response to ACZ885 in patients with Muckle-Wells syndrome (MWS) , oral presentation OP-0178 at EULAR [ EB/OL]. (2008 - 08 - 20). http ://www. abstracts2view, corn/ eular/view, php? nu = EULAR08L_OP4)178 Accessed.
  • 10GATTORNO M, TASSI S, CARTA S, et al. Pattern of interleukin-lbeta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations[J]. Arthritis Rhettm,2007,56(9): 3138 -3148.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部